drugset / Trial / NCT05646563
Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 in PNH patients undergoing complement-inhibitor therapy with Soliris.
Timeline
- Start
- 2027-01
- Primary completion
- 2029-07
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RUXOPRUBART | Monoclonal antibody | 20 mg/kg | Intravenous |
| Background | Eculizumab | Monoclonal antibody | — | Intravenous |